Connor Iapoce

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

A posthoc analysis of the phase 2 CANDELA study presented at ARVO 2023 suggests aflibercept 8 mg improved visual and anatomical outcomes compared with aflibercept 2 mg in eyes with nAMD.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

Phase 3 results presented at ARVO 2023 suggest a switch from aflibercept to SB15 led to no treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

An analysis of 118 infant eyes in India suggests the biosimilar is safe and effective in treating ROP, with about one-third of eyes requiring reinjection at 7 weeks after the first dose.

An analysis of an ethnically diverse cohort in London found African Caribbean people experienced a 39% greater risk of sight-threatening DR, independent of traditional risk factors.

An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.

Patients who had severe COVID-19 infection requiring mechanical ventilation had a 16-fold risk of ventricular tachycardia within 6 months, according to new findings presented at EHRA 2023.

More than 50,000 patients with atrial fibrillation experienced reduced risks of stroke if they started statins within a year of diagnosis, compared with those who did not.

Results from the TEMPO-HCM study suggest that 30-day ECG monitoring in patients with HCM detects more arrhythmias than the standard 24-48 hours.

An analysis of real-world data suggests intravitreal injection of biosimilar ranibizumab in a loading dose followed by a PRN protocol is a viable strategy for treating patients with nAMD.

Many effective anti-obesity medications could be manufactured and sold profitably for a low price, with estimated minimum prices up to 20-fold cheaper than current prices in some countries.

The proportion of premature infants diagnosed with ROP increased from 4.4% in 2003 to 8.1% in 2019, particularly among underserved populations.

A retrospective analysis of more than 3 million patients who received the mRNA COVID-19 vaccine found no association between vaccination and newly diagnosed RVO.

Results from the SELECT-PsA trials indicate patients with active PsA and axial involvement demonstrated greater clinical improvement with upadacitinib 15 mg versus placebo.

According to Horizon Therapeutics, the updated indication language reinforces the importance of access for patients across the full spectrum of TED activity or duration.

The statement suggests the importance of including non-biological factors and social determinants of health in CVD risk assessment for women of diverse races and ethnicities.

A new analysis suggests an association between elevated heart rate and increased risk of developing new-onset T2D, but the effects were largely restricted to younger individuals.

In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.